Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
2.
Clin Infect Dis ; 68(12): 2114-2116, 2019 05 30.
Article in English | MEDLINE | ID: mdl-30561577

ABSTRACT

In a large community-randomized trial, biannual azithromycin distributions significantly reduced postneonatal childhood mortality in sub-Saharan African sites. Here, we present a prespecified secondary analysis showing that much of the protective effect was in the first 3 months postdistribution. Distributing more frequently than biannually could be considered if logistically feasible. Clinical Trials Registration. NCT02047981.


Subject(s)
Anti-Bacterial Agents/administration & dosage , Azithromycin/administration & dosage , Child Mortality , Trachoma/drug therapy , Trachoma/mortality , Child, Preschool , Female , Humans , Infant , Infant Mortality , Infant, Newborn , Male , Mass Drug Administration , Time Factors , Trachoma/epidemiology
3.
Pediatr Infect Dis J ; 37(11): 1082-1086, 2018 11.
Article in English | MEDLINE | ID: mdl-29561511

ABSTRACT

BACKGROUND: Mass distributions of azithromycin for trachoma have been associated with secondary benefits, including reductions in child mortality. METHODS: In the Partnership for the Rapid Elimination of Trachoma cluster-randomized trial in Niger, 24 communities were randomized to annual treatment of everyone and 24 communities were randomized to biannual treatment of children under 12 for 3 years (clinicaltrials.gov, NCT00792922). Treatment was a single dose of directly observed oral azithromycin (20 mg/kg up to 1 g in adults). Vital status was assessed during annual census and monitoring visits. In this prespecified secondary analysis, we compared the mortality rate among children 6 months to less than 5 years of age by treatment arm using negative binomial regression. RESULTS: Among children 6 months to less than 5 years of age, 404 deaths occurred during the study period. The mortality rate was 35.6 deaths per 1000 person-years (231 deaths, 95% CI: 30.9-40.9) in the annual arm and 29.0 deaths per 1000 person-years (173 deaths, 95% CI: 24.8-33.8) in the biannual arm. The mortality rate ratio comparing children in the biannual arm to the annual arm was 0.81 (95% CI: 0.66-1.00, P = 0.07; primary outcome). The mortality rate ratio comparing children who died from infectious causes in the biannual arm to the annual arm was 0.73 (95% CI: 0.57-0.94; P = 0.02). No adverse events were reported. CONCLUSIONS: This secondary analysis of a cluster-randomized trial found a nonsignificant 19% decrease in mortality among children 6 months to less than 5 years of age who received biannual azithromycin compared with children who received annual azithromycin. This study was conducted in a high mortality, trachoma-endemic area; thus, results may be specific to this environment only. In addition, the trial was neither designed nor powered to detect a mortality effect, and we cannot rule out the possibility that mortality differences resulted from bias.


Subject(s)
Anti-Bacterial Agents/administration & dosage , Azithromycin/administration & dosage , Child Mortality , Mass Drug Administration , Administration, Oral , Child , Child, Preschool , Communicable Diseases/drug therapy , Communicable Diseases/epidemiology , Female , Humans , Infant , Male , Niger/epidemiology , Prevalence , Trachoma/drug therapy , Trachoma/epidemiology , Trachoma/mortality
4.
Am J Trop Med Hyg ; 93(5): 1106-9, 2015 Nov.
Article in English | MEDLINE | ID: mdl-26392160

ABSTRACT

A cluster-randomized trial demonstrated that mass oral azithromycin distribution reduced childhood mortality 49.6% (Trachoma Amelioration in Northern Amhara [TANA]). The relative risk of childhood mortality was then estimated using two approaches: an expert survey and a Bayesian analysis. The survey asked public health experts to estimate the true effect of mass azithromycin distribution on childhood mortality. The Bayesian estimation used the TANA study's results and prior estimates of the efficacy of other effective population-level interventions. The experts believed mass azithromycin reduces childhood mortality (relative risk = 0.83, 95% credible intervals [CrI] = 0.70-1.00). The Bayesian analysis estimated a relative risk of 0.71 (95% CrI = 0.39-0.93). Both estimates suggest that azithromycin may have a true mortality benefit, though of a smaller magnitude than found in the single available trial. Prior information about nonantibiotic, population-level interventions may have informed the expert's opinions. Additional trials are needed to confirm a mortality benefit from mass azithromycin.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Azithromycin/therapeutic use , Diarrhea/mortality , Malaria/mortality , Respiratory Tract Infections/mortality , Trachoma/drug therapy , Administration, Oral , Africa South of the Sahara/epidemiology , Bayes Theorem , Child, Preschool , Cluster Analysis , Diarrhea/drug therapy , Diarrhea/prevention & control , Humans , Infant , Malaria/drug therapy , Malaria/prevention & control , Respiratory Tract Infections/drug therapy , Respiratory Tract Infections/prevention & control , Surveys and Questionnaires , Trachoma/mortality , Trachoma/prevention & control , Treatment Outcome
5.
J Epidemiol Glob Health ; 3(4): 269-77, 2013 Dec.
Article in English | MEDLINE | ID: mdl-24206798

ABSTRACT

The purpose of this study was to determine the association between deaths owing to terrorism, civil war and one-sided violence from 1994-2000 and disability-adjusted life years (DALYs) attributable to diarrheal and related diseases, schistosomiasis, trachoma and the nematode infections (DSTN diseases) in 2002 among World Health Organization Member States. Deaths resulting from terrorism, civil war and one-sided violence were significantly related to DSTN DALYs across the majority of sex-age subgroups of the populace, after controlling for baseline levels of improved water/sanitation and a variety of economic measures: overall, a 1.0% increase in deaths owing to terrorism and related violence was associated with an increase of 0.16% in DALYs lost to DSTN diseases. Associations were greatest among 0-to-4-year olds. The results of the present study suggest that DSTN disease control efforts should target conflict-affected populations with particular attention to young children who suffer disproportionately from DSTN diseases in these settings. In view of the evidence that terrorism and related violence may influence DSTN DALYs in the longer term, control strategies should move beyond immediate responses to decrease the incidence and severity of DSTN diseases to seek solutions through bolstering health systems infrastructure development among conflict-affected populations.


Subject(s)
Dysentery/mortality , Nematode Infections/mortality , Schistosomiasis/mortality , Terrorism , Trachoma/mortality , Violence , Warfare , Global Health/economics , Global Health/statistics & numerical data , Humans , Quality-Adjusted Life Years , Regression Analysis , Sanitation/statistics & numerical data , Water Supply/statistics & numerical data
7.
Am J Trop Med Hyg ; 85(3): 518-23, 2011 Sep.
Article in English | MEDLINE | ID: mdl-21896815

ABSTRACT

Trachoma control strategies, including latrine construction and antibiotic distribution, are directed at reducing ocular chlamydia, but may have additional benefits. In a cluster-randomized clinical trial, 24 subkebeles (administrative geographic units) in Ethiopia were offered a single mass azithromycin treatment, and half were randomized to receive an intensive latrine promotion. At a follow-up census 26 months after the baseline treatment, 320 persons had died. The mortality rate of children 1-5 years of age was 3.87 (95% confidence interval [CI] = 2.19-6.82) per 1,000 person-years in the latrine promotion arm, and 2.72 (95% CI = 1.37-5.42) per 1,000 person-years in the control arm. In a multi-level mixed effects logistic regression model controlling for age, there was no difference in mortality in persons randomized into the latrine or control arms (odds ratio = 1.18, 95% CI = 0.89-1.58). Latrine promotion provided no additional effect on mortality in the context of an azithromycin distribution program (clinicaltrials.gov, #NCT00322972).


Subject(s)
Toilet Facilities , Trachoma/mortality , Trachoma/prevention & control , Adolescent , Anti-Bacterial Agents/administration & dosage , Anti-Bacterial Agents/pharmacology , Azithromycin/administration & dosage , Azithromycin/pharmacology , Child , Child, Preschool , Cluster Analysis , Ethiopia/epidemiology , Female , Humans , Infant , Male , Odds Ratio , Trachoma/epidemiology , Young Adult
8.
JAMA ; 302(9): 962-8, 2009 Sep 02.
Article in English | MEDLINE | ID: mdl-19724043

ABSTRACT

CONTEXT: Mass oral azithromycin distribution to affected communities is a cornerstone of the World Health Organization's trachoma elimination program. Antibiotics are provided to target the ocular strains of chlamydia that cause trachoma, but may also be efficacious against respiratory disease, diarrhea, and malaria--frequent causes of childhood mortality in trachoma-endemic areas. OBJECTIVE: To compare mortality rates of participants aged 1 to 9 years in treated communities with those in untreated communities. DESIGN, SETTING, AND PARTICIPANTS: We conducted a cluster-randomized clinical trial of mass azithromycin administration for trachoma control. Forty-eight communities (known as subkebeles) were randomized into 1 of 3 treatment schedules (annual treatment of all residents [15,902 participants], biannual treatment of all residents [17,288 participants], or quarterly treatment of children only [14,716 participants]) or into 1 group for which treatment was delayed by 1 year (control, 18,498 participants). Twelve subkebeles were randomized to each of the 4 schedules with all children in each of the 3 communities being eligible for treatment. The trial was conducted in a field setting in rural Ethiopia, May 2006 to May 2007. INTERVENTIONS: A single dose of oral azithromycin (adults, 1 g; children, 20 mg/kg) was administered for treatment of ocular Chlamydia trachomatis infection. Antibiotic coverage levels for children aged 1 to 9 years exceeded 80% at all visits. MAIN OUTCOME MEASURE: The main outcome measure was the community-specific mortality risk for children aged 1 to 9 years over the course of 1 year. Mortality was measured by enumerative census at baseline and again after 1 year. Comparison of the risk of mortality was a prespecified outcome for the clinical trial. RESULTS: The odds ratio for childhood mortality in the intervention communities was 0.51 (95% confidence interval, 0.29-0.90; P = .02; clustered logistic regression) compared with the control group. In the treated communities, the estimated overall mortality rate during this period for children aged 1 to 9 years in the untreated group was 8.3 per 1000 person-years (95% confidence interval, 5.3-13.1), while among the treated communities, the estimated overall mortality rate was 4.1 per 1000 person-years (95% confidence interval, 3.0-5.7) for children aged 1 to 9 years. CONCLUSION: In a trachoma-endemic area, mass distribution of oral azithromycin was associated with reduced mortality in children. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00322972.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Antibiotic Prophylaxis , Azithromycin/therapeutic use , Trachoma/prevention & control , Anti-Bacterial Agents/administration & dosage , Azithromycin/administration & dosage , Child , Child Mortality , Child, Preschool , Ethiopia/epidemiology , Humans , Infant , Infant Mortality , Rural Population , Trachoma/drug therapy , Trachoma/mortality , Treatment Outcome
9.
Kango ; 39(5): 104-5, 1987 May.
Article in Japanese | MEDLINE | ID: mdl-3650542
10.
Br J Ophthalmol ; 59(10): 600-4, 1975 Oct.
Article in English | MEDLINE | ID: mdl-1191619

ABSTRACT

The prevalence and distribution of trachoma in the Sudan has been studied. The morbidity rate of 83.2 per 1000 in the Northern Province decreases southwards until it reaches 0.94 in the extreme south (Equatoria Province). 2. In endemic areas infection starts very early--in the first year of life. 3. There is a marked difference between the prevalence of trachoma in towns and villages--71.3 per cent for the age group 1-4 years in villages, and 56.7 per cent for the same age group in the towns. This is probably due to better standards of living and hygiene in the towns. 4. Some relationship has been found between the rainfall, the relative humidity, and the incidence of trachoma, but this does not necessarily apply in other countries. 5. The factors that may explain the high prevalence of trachoma in the northern Sudan are: a. Mechanical trauma caused by frequent sandstorms. b. Irritation of the eyes by dust particles, leading to excessive watering and discharge, and rubbing with the fingers. c. The habit of frequent hand-shaking. d. Poor personal hygiene in pre-schoolchildren. e. Associated bacterial conjunctivitis. f. The presence of eye-seeking flies.


Subject(s)
Trachoma/epidemiology , Adolescent , Age Factors , Child , Child, Preschool , Conjunctivitis/epidemiology , Diptera , Geography , Hot Temperature , Humans , Humidity , Hygiene , Infant , Maps as Topic , Rain , Socioeconomic Factors , Sudan , Trachoma/mortality
SELECTION OF CITATIONS
SEARCH DETAIL
...